Head & Neck Cancers | Specialty

Nivolumab in HNSCC

July 7th 2017

Pembrolizumab in HNSCC

July 7th 2017

Checkpoint Inhibitors for Recurrent HNSCC

July 7th 2017

Checkpoint Inhibitors in HNSCC

July 7th 2017

Dr. Siegel Discusses RT-Related AEs for Patients With Oropharyngeal Squamous Cell Carcinomas

July 6th 2017

Robert Siegel, MD, chair, professor of medicine, director, Division of Hematology/Oncology, George Washington University, discusses the adverse events (AEs) associated with radiation therapy (RT) for patients with oropharyngeal squamous cell carcinomas.

Dr. Ferris on Pembrolizumab and Nivolumab in Head and Neck Cancer

June 27th 2017

Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and co-leader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, discusses nivolumab (Opdivo) and pembrolizumab (Keytruda) for patients with head and neck cancer.

Dr. Machiels on Challenges and Ongoing Trials in Head and Neck Cancer

June 27th 2017

Jean-Pascal Machiels, MD, head of the Department of Medical Oncology, Cliniques Universitaires Sain-Luc, discusses challenges still facing the field of head and neck cancer and ongoing trials with a goal to improve patient outcomes.

Expert Hopes Nivolumab/CRT Combo Will Advance Head and Neck Cancer Care

June 26th 2017

Robert Ferris, MD, PhD, discusses the RTOG 3504 trial, as well as the utility of immunotherapy agents for patients with intermediate and high-risk head and neck squamous cell carcinoma.

Dr. Ferris on the Safety Profile for RTOG 3504 for Head and Neck Cancer

June 23rd 2017

Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and co-leader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, discusses the safety profile of the RTOG 3504 trial for patients with head and neck cancer.

Dr. Machiels on Pembrolizumab in Head and Neck Cancer

June 23rd 2017

Jean-Pascal Machiels, MD, head of the Department of Medical Oncology, Cliniques Universitaires Sain-Luc, discusses pembrolizumab (Keytruda) in patients with head and neck cancer.

Dr. Ferris on Combining Immunotherapy and Radiation Therapy in Head and Neck Cancer

June 22nd 2017

Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and co-leader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, discusses the rationale for combining radiation therapy with immunotherapy for the treatment of patients with head and neck cancer.

Dr. Machiels on Toxicities with Pembrolizumab for Head and Neck Cancer

June 20th 2017

Jean-Pascal Machiels, MD, head of the Department of Medical Oncology, Cliniques Universitaires Sain-Luc, discusses toxicities with pembrolizumab (Keytruda) in combination with chemoradiation for patients with head and neck cancer.

Dr. Lee on Combining Anti-PD-L1 to Standard of Care for Head and Neck Cancer

June 20th 2017

Nancy Y. Lee, MD, vice chair, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, discusses the combination of a PD-L1 inhibitor to the standard of care for patients with head and neck cancer.

Dr. Ferris on Immunotherapy in Locally Advanced Head and Neck Cancer

June 19th 2017

Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and co-leader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, discusses immunotherapy in patients with locally advanced head and neck cancer.

Lenvatinib Significantly Extends OS in Older Patients With Thyroid Cancer

June 19th 2017

Lenvatinib (Lenvima) significantly improved overall survival in patients older than 65 years with radioiodine-refractory differentiated thyroid cancer.

Dr. Machiels on Ongoing Trial of Pembrolizumab Plus Chemoradiation in HNSCC

June 14th 2017

Jean-Pascal Machiels, MD, head of the Department of Medical Oncology, Cliniques Universitaires Sain-Luc, discusses an ongoing clinical trial of pembrolizumab (Keytruda) combined with chemoradiation in patients with locally advanced head and neck squamous cell carcinoma (HNSCC).

Dr. Lee on the Impact of Immunotherapy in Head and Neck Cancer

June 14th 2017

Nancy Y. Lee, MD, vice chair, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, discusses the impact of immunotherapy in head and neck cancer.

Dr. Ferris Discusses the RTOG 3504 Study in Head and Neck Cancer

June 13th 2017

Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and co-leader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute discusses the RTOG 3504 study in head and neck cancer.

Epacadostat/ Nivolumab Shows Promising Efficacy for Melanoma, Head and Neck Cancer

June 6th 2017

The combination of the IDO inhibitor epacadostat and nivolumab demonstrated promising signs of activity for patients with squamous cell carcinoma of the head and neck and those with melanoma.

Analysis Finds Similar Efficacy Between Chemoradiation Regimens in SCCHN

June 1st 2017

An analysis in locally advanced squamous cell carcinoma of the head and neck showed that weekly low-dose schedules of chemoradiotherapy produce comparable survival outcomes and response rates as the standard 3-weekly schedule.